| Market Cap | 5.35M | P/E | - | EPS this Y | 97.70% | Ern Qtrly Grth | - |
| Income | -8.29M | Forward P/E | -0.54 | EPS next Y | 80.00% | 50D Avg Chg | -9.00% |
| Sales | 2.63M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -73.00% |
| Dividend | N/A | Price/Book | 0.34 | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | 2.50 | Quick Ratio | 1.39 | Shares Outstanding | 122.68M | 52W Low Chg | 19.00% |
| Insider Own | 8.82% | ROA | -49.09% | Shares Float | 22.68M | Beta | 1.42 |
| Inst Own | 1.89% | ROE | -114.11% | Shares Shorted/Prior | 1.22M/151.59K | Price | 1.32 |
| Gross Margin | 70.16% | Profit Margin | - | Avg. Volume | 92,443 | Target Price | 10.00 |
| Oper. Margin | -281.15% | Earnings Date | May 13 | Volume | 137,904 | Change | -10.81% |
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
| Maxim Group | Hold | Feb 5, 24 |
| Maxim Group | Buy | Apr 3, 23 |
| Maxim Group | Buy | Feb 15, 23 |
| Maxim Group | Buy | Jan 20, 23 |